Contact a Rep
Patients HCP
This site is for US Health Care Professionals only.

PLUVICTO® is now approved in combination with ARPI therapy for patients with PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1

PLUVICTO is the first and only FDA-approved, PSMA-targeted therapy to significantly delay progression in mHSPC and mCRPC.1
 

In PSMA+ mHSPC and PSMA+ mCRPC,

Choose PLUVICTO at the earliest eligible opportunity

PLUVICTO: For your patients across the continuum of metastatic prostate cancer

PLUVICTO in mHSPC patient quadrant

PLUVICTO in mHSPC

For patients with mHSPC (+ ARPI) at any point after diagnosis1,2

PLUVICTO in mCRPC patient quadrant

PLUVICTO in mCRPC

For patients with mCRPC after only 1 ARPI, received at any point in the prostate cancer journey1,3,*

*For patients considered appropriate to delay taxane-based chemotherapy.1

Choose PLUVICTO: Proven in three phase 3 clinical trials.† And ~30K patients treated since FDA approval.1-5,‡

See the data behind PLUVICTO

ARPI, androgen receptor pathway inhibitor; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

†PLUVICTO was studied in 1 clinical trial of mHSPC and 2 clinical trials of mCRPC.1,3,4
‡Based on data from March 2026.5

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. PLUVICTO PSMAddition trial. Novartis Pharmaceuticals Corp; June 2026. 3. Morris MJ, Castellano D, Herrmann K, et al; PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2 4. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 5. Data on file. PLUVICTO NPS Metrics. Novartis Pharmaceuticals Corp; March 2026.